美国制药巨头艾伯维（AbbVie）今日盘前股价大涨5.12%，引发市场广泛关注。这一显著涨幅主要源于公司发布的积极财报和上调的年度盈利预期。
根据公司最新公布的财报，艾伯维第二季度业绩超出华尔街预期。公司季度调整后每股收益达2.97美元，高于分析师平均预期的2.88美元。尤其值得注意的是，公司较新的免疫学药物Skyrizi和Rinvoq表现亮眼。Skyrizi的季度销售额达44.2亿美元，超过预期的40亿美元；Rinvoq销售额为20.3亿美元，同样超过预期的19.7亿美元。
受此鼓舞，艾伯维上调了2025年的盈利预期。公司现预计调整后的年度每股利润在11.88美元至12.08美元之间，高于此前11.67美元至11.87美元的预期。艾伯维首席执行官罗伯特·迈克尔表示："我们正以强劲的势头进入下半年。"这一系列利好消息推动了投资者的信心，导致公司股价在盘前交易中大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.